Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tiziana Life Sciences PLC

1.13
+0.05505.14%
Volume:232.13K
Turnover:253.80K
Market Cap:122.72M
PE:-8.43
High:1.13
Open:1.07
Low:1.01
Close:1.07
Loading ...

BRIEF-Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab In Phase 2 Multiple Sclerosis Clinical Trial

Reuters
·
02 Apr

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

THOMSON REUTERS
·
02 Apr

Tiziana Life Sciences files $250M mixed securities shelf

TIPRANKS
·
26 Mar

Tiziana Life Sciences announces dosing of new patients at Yale MS Center

TIPRANKS
·
26 Mar

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

THOMSON REUTERS
·
25 Mar

Stocks to Watch Tuesday: Trump Media, Tesla, Samsung, GameStop -- WSJ

Dow Jones
·
25 Mar

BRIEF-Tiziana Life Sciences Ltd Files For Mixed Shelf Of Up To $250 Million - SEC Filing

Reuters
·
25 Mar

Tiziana Life Sciences Ltd Files for Mixed Shelf of up to $250 Mln - SEC Filing

THOMSON REUTERS
·
25 Mar

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

GlobeNewswire
·
17 Mar

Tiziana Life Sciences Regains Compliance With Nasdaq Listing Rule

MT Newswires Live
·
14 Mar

Tiziana Life Sciences Regains Compliance With Nasdaq Listing Minimum Bid Price Rule

THOMSON REUTERS
·
14 Mar

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential

Simply Wall St.
·
14 Mar

Tiziana Life Sciences Files New Drug Application for ALS Drug Candidate

MT Newswires Live
·
04 Mar

BRIEF-Tiziana Life Sciences Files Investigational New Drug Application With FDA For ALS Phase 2 Clinical Trial

Reuters
·
04 Mar

Tiziana Life Sciences files IND application with FDA for ALS Phase 2 trial

TIPRANKS
·
04 Mar

Tiziana Life Sciences Files Investigational New Drug Application With FDA for ALS Phase 2 Clinical Trial

THOMSON REUTERS
·
04 Mar

Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025

Insider Monkey
·
02 Mar

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

GlobeNewswire
·
27 Feb

Tiziana : Nasal Anti-Cd3 (Foralumab) Preclinical Study Nearing Completion, Foralumab Could Offer Treatment for Long Covid

THOMSON REUTERS
·
25 Feb

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

GlobeNewswire
·
25 Feb